Institution
Manipal University
Education•Manipal, Karnataka, India•
About: Manipal University is a education organization based out in Manipal, Karnataka, India. It is known for research contribution in the topics: Population & Medicine. The organization has 9525 authors who have published 11207 publications receiving 110687 citations.
Topics: Population, Medicine, Computer science, Health care, Cancer
Papers published on a yearly basis
Papers
More filters
••
University of Alberta1, University of British Columbia2, University of Calgary3, University of Ottawa4, University of Yaoundé I5, Saint Louis University6, University of Hassan II Casablanca7, University of Oxford8, Singapore General Hospital9, The George Institute for Global Health10, Manipal University11, University of California, Los Angeles12, University of California, Irvine13, Monash Medical Centre14, Monash University, Clayton campus15, University of Tennessee Health Science Center16, Veterans Health Administration17, University of Zurich18, Brigham and Women's Hospital19, Salford Royal NHS Foundation Trust20, University of Manchester21, Iran University of Medical Sciences22, University of Toronto23, St. Michael's Hospital24, University of Paris25, University of Melbourne26, Tbilisi State Medical University27, Charles University in Prague28, King Chulalongkorn Memorial Hospital29, Bezmialem Foundation University30, University of Hong Kong31, Chang Gung University32, Memorial Hospital of South Bend33, First Pavlov State Medical University of St. Peterburg34, Public Health Research Institute35, North Bristol NHS Trust36, University of Bristol37, University of Cape Town38, Pan American Health Organization39, University of Leicester40, University of Sydney41, Princess Alexandra Hospital42, Translational Research Institute43, University of Queensland44
TL;DR: These comprehensive data show the capacity of countries (including low income countries) to provide optimal care for patients with end stage kidney disease and demonstrate substantial variability in the burden of such disease and capacity for kidney replacement therapy and conservative kidney management, which have implications for policy.
Abstract: Objective To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management. Design International cross sectional survey. Setting International Society of Nephrology (ISN) survey of 182 countries from July to September 2018. Participants Key stakeholders identified by ISN's national and regional leaders. Main outcome measures Markers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management. Results Responses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (<10%) of 53 African countries reported these data. Of 159 countries, 102 (64%) provided public funding for kidney replacement therapy. Sixty eight (43%) of 159 countries charged no fees at the point of care delivery and 34 (21%) made some charge. Haemodialysis was reported as available in 156 (100%) of 156 countries, peritoneal dialysis in 119 (76%) of 156 countries, and kidney transplantation in 114 (74%) of 155 countries. Dialysis and kidney transplantation were available to more than 50% of patients in only 108 (70%) and 45 (29%) of 154 countries that offered these services, respectively. Conservative kidney management was available in 124 (81%) of 154 countries. Worldwide, the median number of nephrologists was 9.96 per million population, which varied with income level. Conclusions These comprehensive data show the capacity of countries (including low income countries) to provide optimal care for patients with end stage kidney disease. They demonstrate substantial variability in the burden of such disease and capacity for kidney replacement therapy and conservative kidney management, which have implications for policy.
111 citations
••
TL;DR: A review of the synthesis and pharmacological properties of chalcone derivatives highlights the important antimicrobial, antifungal, anti-mycobacterial, antimalarial, antiviral,Anti-inflammatory, antioxidant, antileishmanial anti-tumor, and anticancer properties.
Abstract: Chalcones and their analogs have been an area of great interest in recent years. Numerous research papers have been published, and chalcones continue to show promise for new drug investigations. Researchers have explored new approaches for the synthesis of chalcone derivatives, which have revealed an array of pharmacological and biological effects. These chalcone derivatives have shown important antimicrobial, antifungal, anti-mycobacterial, antimalarial, antiviral, anti-inflammatory, antioxidant, antileishmanial anti-tumor, and anticancer properties. This review highlights the synthesis and pharmacological properties of chalcone derivatives.
111 citations
••
TL;DR: Effects of chitosan‐coated tissue culture plates on adhesion and osteoblast differentiation processes of human mesenchymal stem cells, isolated from adult bone marrow are evaluated.
Abstract: Objectives: Chitosan is widely used as a scaffold for bone tissue engineering. However, up-to-date, no previous detailed study has been conducted to elucidate any mechanism of osteogenesis by chitosan itself. Here, we have evaluated effects of chitosan-coated tissue culture plates on adhesion and osteoblast differentiation processes of human mesenchymal stem cells (hMSCs), isolated from adult bone marrow.
Materials and methods: Tissue culture plates coated with chitosan at different coating densities were used to evaluate the effects on hMSC adhesion and osteoblast differentiation. hMSCs were induced to differentiate into osteoblasts on the chitosan-coated plates and were evaluated using established techniques: alkaline phosphatase assay, demonstration of presence of calcium and real time PCR.
Results: The cells adhered to plates of lower coating density of chitosan, but formed viable cell aggregates at higher coating density (100 μg/sq.cm). Coating density of 25 μg/sq.cm, supporting cell adhesion was chosen for osteoblast differentiation experiments. Differentiating hMSCs showed higher mineral deposition and calcium content on chitosan-coated plates. Chitosan upregulated genes associated with calcium binding and mineralization such as collagen type 1 alpha 1, integrin-binding sialoprotein, osteopontin, osteonectin and osteocalcin, significantly.
Conclusions: We demonstrate for the first time that chitosan enhanced mineralization by upregulating the associated genes. Thus, the study may help clinical situations promoting use of chitosan in bone mineralization, necessary for healing non-union fractures and more.
110 citations
••
TL;DR: In this article, the authors point out the various 3D printing technologies and their applications in research for fabricating pharmaceutical products, along with their pros and cons, and an approach of how it can be used in a clinical setting.
Abstract: Personalized medicine has the potential to revolutionize the healthcare sector, its goal being to tailor medication to a particular individual by taking into consideration the physiology, drug response, and genetic profile of that individual. There are many technologies emerging to cause this paradigm shift from the conventional "one size fits all" to personalized medicine, the major one being three-dimensional (3D) printing. 3D printing involves the establishment of a three-dimensional object, in a layer upon layer manner using various computer software. 3D printing can be used to construct a wide variety of pharmaceutical dosage forms varying in shape, release profile, and drug combination. The major technological platforms of 3D printing researched on in the pharmaceutical sector include inkjet printing, binder jetting, fused filament fabrication, selective laser sintering, stereolithography, and pressure-assisted microsyringe. A possible future application of this technology could be in a clinical setting, where prescriptions could be dispensed based on individual needs. This manuscript points out the various 3D printing technologies and their applications in research for fabricating pharmaceutical products, along with their pros and cons. It also presents its potential in personalized medicine by individualizing the dose, release profiles, and incorporating multiple drugs in a polypill. An insight on how it tends to various populations is also provided. An approach of how it can be used in a clinical setting is also highlighted. Also, various challenges faced are pointed out, which must be overcome for the success of this technology in personalized medicine.
110 citations
••
TL;DR: Overall, using this approach, a number of promising novel candidates are identified that can be validated further for their potential to serve as biomarkers for ESCC.
Abstract: Cancer of the esophagus is of two main types, each with distinct etiological and pathological characteristics. Esophageal squamous cell carcinoma (ESCC) is predominant type of esophageal cancers worldwide comprising almost 95% of cases. While ESCC is prevalent in the developing world, esophageal adenocarcinoma is commonly seen in the developed country, usually in association with Barrett's esophagus. In spite of its higher prevalence, ESCC has not been studied as intensively as esophageal adenocarcinoma. ESCC and esophageal adenocarcinoma are common cancers worldwide with poor survival rate among patients mainly because both of these cancers lack early biomarkers of identification. Molecular mechanisms contributing to initiation and progression of esophageal squamous cell carcinoma are still poorly understood. Development of DNA microarray technology allows high-throughput identification of gene expression profiles in cancers. In order to identify molecules as candidates for early diagnosis and/or as therapeutic targets, we analyzed the mRNA expression profiles of 20 cases of ESCC using whole genome DNA microarrays. A total of 2,235 genes were differentially regulated in the tumors as compared to the corresponding adjacent normal epithelium of which 881 were significantly upregulated. We validated two molecules that were not previously reported to be overexpressed in ESCC, oral cancer overexpressed 2 (ORAOV2) and fibroblast activation protein (FAP), by immunohistochemical labeling of tissue microarrays and archival tissue sections and found that they were overexpressed in 98% (116/118) and 68% (79/116) of cases, respectively. By gene enrichment analysis, we identified significant downregulation of several genes in the arachidonic acid metabolic pathway. Overall, using this approach we have identified a number of promising novel candidates that can be validated further for their potential to serve as biomarkers for ESCC.
110 citations
Authors
Showing all 9740 results
Name | H-index | Papers | Citations |
---|---|---|---|
John J.V. McMurray | 178 | 1389 | 184502 |
Ashok Kumar | 151 | 5654 | 164086 |
Zhanhu Guo | 128 | 886 | 53378 |
Vijay P. Singh | 106 | 1699 | 55831 |
Michael Walsh | 102 | 963 | 42231 |
Akhilesh Pandey | 100 | 529 | 53741 |
Vivekanand Jha | 94 | 958 | 85734 |
Manuel Hidalgo | 92 | 538 | 41330 |
Madhukar Pai | 89 | 522 | 33349 |
Ravi Kumar | 82 | 571 | 37722 |
Vijay V. Kakkar | 60 | 470 | 17731 |
G. Münzenberg | 58 | 336 | 9837 |
Abhishek Sharma | 52 | 426 | 9715 |
Ramesh R. Bhonde | 49 | 223 | 8397 |
Chandra P. Sharma | 48 | 325 | 12100 |